Hosted on MSN
Tryptamine’s world-first psilocin based IV-infusion meets key objectives in phase 1b study
Tryptamine’s phase 1b study of IV-infused psilocin meets all objectives Lead asset TRP-8803 found safe at low, mid and upper dose levels Planning underway to advance TRP-8803 in phase II trials ...
The research, which builds on previous work, eventually may lead to a more objective diagnostic tool, scientists said. By Teddy Rosenbluth The process for diagnosing a child with autism heavily relies ...
Tryptamine Therapeutics (ASX:TYP) has provided further data from its recently completed phase 1b study utilising TRP-8803, with all key objectives met including: TRP-8803 safe at low, mid, and upper ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback